FDA Approvals in Oncology: July-September 2025
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
Category: FDA Approvals
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
In the second quarter of 2025, the FDA issued 13 new oncology approvals, including options for rare cancers, head...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
FDA approvals issued in third quarter 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...